Resource Centers
- New Guidelines on H1N1 Influenza Urge Quicker Use of Antivirals
- Pulmonary Embolism and Drug Reactions Top List of Diagnostic Errors
- SGR Repair Bill Failure Could Cool Physician Support for Healthcare Reform
- The Family Practitioner and Health Reform: An Expert Interview With Ted Epperly, MD, FAAFP
- Alert FDA Commissioner Addresses H1N1 Vaccine Safety Concerns
Business of Medicine Journals
Medscape Community Resources
POLL
In a BMJ editorial published last month, mandatory screening of all electively admitted patients for MRSA in UK hospitals was criticized for being "unethical" and "unjustified," citing it as potentially harmful because of a potential delay in treatment. Do you favor or oppose mandatory screening for MRSA in hospitalized patients?
- A Treatment Option for Atrial Fibrillation
- A single medication with 4 indications
- A treatment option for ACS and DVT/PE
- ABILIFY® (aripiprazole)
- ACUVUE® Brand Contact Lenses
- ADHD treatment: Efficacy, insights, and dosing
- ALIMTA® (pemetrexed for injection)
- AMBIEN CR® (zolpidem tartrate extended-release CIV)
- Argatroban
- Atrial Fibrillation Condition Site
- COSAMIN®DS
- CRESTOR® (rosuvastatin calcium)
- Carac® (fluorouracil cream 0.5%)
- Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension
- Clinical Management Center
- DanActive® and ACTIVIA® Information Center
- Diabetes in America
- ENABLEX® (darifenacin) Extended-Release Tablets 7.5 mg or 15 mg
- Epilepsy360: Connections in Care
- GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
- GEMZAR® (gemcitabine HCI)
- GEODON® (ziprasidone HCI)
- Genomic Advances in Cardiovascular Care
- Heartmate II® Left Ventricular Assist System
- IL-6 and Rheumatoid Arthritis
- ISENTRESS® (raltegravir) Tablets
- Institute for Advances in Point-of-Care Testing
- Kidney Transplantation
- LEVAQUIN® (levofloxacin) tablets/injection
- LOVAZA® (omega-3-acid ethyl esters)
- NEW INTUNIV™ (guanfacine) Extended Release Tablets
- NUCYNTA™ (tapentadol)
- NUVIGIL® (armodafinil) Tablets [C-IV]
- Navigenics® Genetic Risk Assessment Services
- Neuroendocrine tumors: Increasing in incidence and easy to overlook
- Neutrogena® Pure & Free™ Baby Sunblock Lotion
- OPTIMAL Forum™
- Onglyza™ (saxagliptin) InfoSite
- PEGASYS (peginterferon alfa-2a) for injection
- PREMARIN® (conjugated estrogens tablets, USP)
- PRISTIQ® (desvenlafaxine)
- ProAir® HFA
- Professional Liability Risk: Facts, Perspectives, and Management Strategies InfoSite
- QuickVue® Influenza A+B Test
- REBIF® (interferon beta-1a)
- RITUXAN® (Rituximab)
- Reclast® (zoledronic acid) injection
- Research VEGF: Emerging Research Around Targeting VEGF
- Risk of Osteoporosis
- SANDOSTATIN® LAR DEPOT (octreotide acetate for injectable suspension)
- Survivorship and Early Breast Cancer Information
- Symbyax® (Olanzapine and Fluoxetine HCl Capsules)
- TOVIAZ® (fesoterodine fumarate)
- Talecris Hypermunes™
- Targeted Biologic Therapy in Breast Cancer
- Targeting CD20: Scientific Insights and Implications for Therapy
- The HER signaling network and cancer
- The Pain Institute
- The Science of Facial Aging
- Treatment of Pulmonary Arterial Hypertension
- VESIcare (solifenacin succinate) tablets
- VIGAMOX® solution
- Vyvanse (lisdexamfetamine dimesylate)
- XYZAL® (levocetirizine dihydrochloride)
Advisory Board
- George S. Conomikes, BA, MA
- Jeffrey J. Denning
- Eric S. Fishman, MD
- Gregory A. Hood, MD
- Brian Kern, Esq.
- Kathryn I. Moghadas, RN, CLRM, CHBC, CPC, CHCC
- Joseph E. Scherger, MD, MPH
- Robert C. Scroggins, JD, CPA, CHBC
- Elizabeth Woodcock, MBA
Site Editorial Directors
Site Editor
